Regulation of Drug Marketing: An Introduction

Learn to differentiate between “label” and “labeling” and “false and “misleading”. Gain insight on FDA’s social media guidance, use of off-label information, and considerations for other government and state entities. Understand the role of a corporate compliance program in managing the risks of marketing a drug.

Laura S. Dona, Associate, Arnall Golden Gregory LLP
Alan G. Minsk, Partner and Co-Chair of Food and Drug Practice Team, Arnall Golden Gregory LLP

This session was recorded as part of FDLI’s Introduction to Drug Law and Regulation Course in November 2023. 

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content